What is GYRE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.75B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GYRE?

P/E (TTM) is n/a and 52-week range is $5.44 to $9.42 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GYRE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GYRE?

The company profile lists revenue (TTM) near $108M, net income (TTM) near $-1.58B, EPS (TTM) near $-0.18 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Gyre Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 91.4M shares outstanding, ISIN US4037831033 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Gyre Therapeutics Inc

$GYRE

Health Care · Biotechnology

IR Run Scenarios

$7.04

+4.14%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The company is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.

Employees

618

Website

www.gyretx.com/

IPO

2006-04-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)